site stats

Dyne therapeutics ipo

WebMar 20, 2024 · Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases. With its proprietary FORCE™ platform, Dyne is developing modern oligonucleotide therapeutics that are designed to overcome limitations in delivery to … WebMar 23, 2024 · Dyne Therapeutics sets IPO terms, to offer 10.3 million shares priced at $16 to $18 each. Sep. 10, 2024 at 7:12 a.m. ET by Ciara Linnane.

Dyne Therapeutics - Crunchbase Company Profile & Funding

WebApr 11, 2024 · Dyne Therapeutics Trading Down 6.0 %. DYN stock opened at $8.82 on Tuesday. The firm has a 50 day moving average of $12.59 and a 200-day moving average of $12.09. The firm has a market ... WebSep 17, 2024 · Dyne Therapeutics’ IPO and CureDuchenne’s timely funding is an exemplary model of the CureDuchenne venture philanthropy approach. The CureDuchenne Ventures investment made at a critical time in March 2024 helped Dyne de-risk the science and establish proof-of-concept. They were able to keep working, … jelena ilic glumica biografija https://aileronstudio.com

The Daily Biotech Pulse: Moderna Inks 2 R&D Deals, BioNTech To …

WebMar 14, 2024 · 天眼查为您提供Dyne Therapeutics Inc.的企业信息查询服务，查询Dyne Therapeutics Inc.工商注册信息、公司电话、公司地址、公司邮箱网址、公司经营风险、公司发展状况、公司财务状况、公司股东法人高管、商标、融资、专利、法律诉讼等Dyne Therapeutics Inc.企业信用信息，想了解Dyne Therapeutics Inc.怎么样，就 ... WebMar 20, 2024 · WALTHAM, Mass., March 20, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. DYN, a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people ... WebMay 14, 2024 · WALTHAM, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, is presenting new preclinical data from its myotonic dystrophy type 1 (DM1) program … lahntal liebe

Dyne Therapeutics, Inc. (DYN) - Stock Analysis

Category:Dyne Therapeutics, Inc. IPOScoop

Tags:Dyne therapeutics ipo

Dyne therapeutics ipo

Dyne Therapeutics - Crunchbase Company Profile & Funding

WebSep 1, 2024 · Dyne Therapeutics (DYN) aims to raise $100 million in an IPO of its common stock, according to an S-1 registration statement. The … WebApr 4, 2024 · Ticker Symbol: DYN: Exchange: NASDAQ: Fiscal Year: January - December: Reporting Currency: USD: IPO Price: $19.00: CIK Code: 0001379895: CUSIP Number: …

Dyne therapeutics ipo

Did you know?

WebAug 26, 2024 · Wednesday’s spinout was prompted by a massive $1.5-plus billion buyout of Tizona by Gilead, announced earlier this month. That agreement gave Gilead 49.9% ownership of ... WebSep 17, 2024 · Waltham, Massachusetts-based Dyne Therapeutics, Inc. priced its upsized initial public offering of 12.253 million shares at $19 versus the estimated price range of $16 and $18, to generate gross ...

WebAug 25, 2024 · Dyne Therapeutics, a preclinical biotech developing therapies for muscular diseases, filed on Tuesday with the SEC to raise up to $100 million in an initial public offering. The company is using ... WebSep 10, 2024 · Dyne Therapeutics (DYN), a developer of therapies for muscle diseases plans an IPO of 10.3M shares, to be priced in a range of $16 to $18.J.P.

WebSep 17, 2024 · IPOs. Waltham, Massachusetts-based Dyne Therapeutics, Inc. priced its upsized initial public offering of 12.253 million shares at $19 versus the estimated price … Web26 rows · Dyne Therapeutics, Inc. Financial Information: Market Cap: $707.8mil: Revenues: $0 mil (last 12 ...

WebSep 12, 2024 · Dyn Therapeutics (DYN) has filed to raise $175 million from the sale of its common stock in an IPO, according to an amended registration statement.. The company is a preclinical stage developer of ...

WebSep 22, 2024 · Dyne Therapeutics, Inc. rings the Nasdaq Closing Bell remotely from across the country. In celebration of its IPO, Joshua Brumm, President & CEO, rings the Opening Bell alongside the Company’s ... jelena ilic psihologlahntalliebeWebApr 11, 2024 · Dyne Therapeutics has a 52-week low of $4.30 and a 52-week high of $15.63. Dyne Therapeutics ( NASDAQ:DYN - Get Rating ) last issued its quarterly earnings data on Thursday, March 2nd. The company reported ($0.74) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.84) by $0.10. jelena helblingWebDec 23, 2024 · December 23, 2024 7:16 P.M. After raising $267.7 million in gross proceeds from its September initial public offering, Dyne Therapeutics Inc. signed a lease this month to occupy the entire three ... jelena ilic lavoroWebSep 17, 2024 · CureDuchenne celebrates Dyne Therapeutics’ public offering on the Nasdaq, under the ticker “DYN”. Today’s initial public offering (IPO) will elevate Dyne’s financial position and accelerate Dyne’s lead programs, which includes Duchenne muscular dystrophy. CureDuchenne values companies like Dyne that utilize fundraising tools such … jelena ilic fotoWebSep 17, 2024 · A muscle disease company, Dyne Therapeutics (DYN) has priced its IPO of 12,251,578 common shares at $19.00/share, for expected gross proceeds of … lahntalhausWebSep 10, 2024 · Dyne Therapeutics, a preclinical biotech developing oligonucleotide therapies for rare muscular diseases, announced terms for its IPO on Thursday. The … lahntal leben im wald